Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients.

Scott JewSean BujarskiBernard RegidorMarsiye Emamy-SadrRegina SwiftBenjamin EadesSusanna KimShahrooz EshaghianJames R Berenson

Published in: Targeted oncology (2023)

These results provide clinicians with a real-world understanding of the survival of unselected, newly diagnosed patients initiating therapy in a clinic specializing in the care of MM patients.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
multiple myeloma
primary care
peritoneal dialysis
quality improvement
pain management
health insurance
patient reported
cell therapy
free survival